Zenas BioPharma
Update in progressZBIO (NasdaqGS)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Zenas BioPharma, Inc. is a clinical-stage biopharma company focused on immunology-based therapies. Its lead candidate, obexelimab, is a bifunctional antibody targeting CD19 and FcγRIIb for various inflammatory and immunology indications, including IgG4-related disease, multiple sclerosis, and systemic lupus erythematosus. Other programs include ZB002 (anti-TNFα), ZB004 (extended-half-life CTLA-4-Ig), and ZB001 (anti-IGF-1R). Founded 2019, headquartered in Waltham, MA; renamed in 2023 from Zenas BioPharma (Cayman) Limited.
Company score
- Sentiment
- 0.18
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.14
- Governance
- -0.02
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.04
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!